A Brutal Day in the Market
Shares of Hims & Hers tumbled roughly 10% following a quarterly earnings report that fell short on nearly every metric investors had been watching. The stock had been climbing higher into the print, fueled by enthusiasm around a newly announced partnership with Novo Nordisk and growing chatter about the company being first to market with peptides ahead of the summer. Yet when the numbers landed, they were not enough to satisfy the street. The result was an abrupt and painful repricing.
The headline figures tell the story clearly. The company reported a first-quarter loss of 40 cents per share, a stark reversal from a 20-cent profit in the same period a year earlier. Analysts had been looking for a profit of 3 cents per share, making the swing into the red a particularly hard pill to swallow. Revenue rose only about 3.7%, missing analyst expectations that had been set north of $616 million. The forward-looking second-quarter revenue guidance of $680 million to $700 million did come in above the $643 million consensus, but a better outlook was not enough to offset the disappointment of the quarter just past.
The Cost of a Strategic Pivot
Much of the pain in the quarter traces back to a fundamental shift in the company's business model. During the COVID pandemic, Hims & Hers rose to prominence in part because it could compound GLP-1 weight loss drugs during a period of acute shortage. A regulatory gray area allowed the company to manufacture similar products in a time of scarcity, and it leaned heavily into that opportunity. Once shortages ended, however, that edge evaporated. Novo Nordisk sued over the continued production of compounded versions of its drugs at a time when no shortage existed, and the resulting settlement reshaped the company's strategy.
The pivot has been expensive. Hims & Hers is now selling Wegovy and Ozempic on its platform, but moving toward name-branded medications carries higher costs and squeezes margins. The quarter included a $33.5 million restructuring charge, inventory write-downs, and third-party costs tied to the transition. These pressures are unlikely to disappear quickly, and they help explain why the company is losing market share in the GLP-1 space that has been its bread and butter.
A Bright Spot in Subscribers
Not all the news was grim. Subscriber counts climbed to 2.6 million at the end of the first quarter, up from 2.5 million at the end of 2025. Because the business is built around a direct-to-consumer subscription model with integrated telehealth communications, subscriber growth remains the most important indicator of underlying engagement. The trajectory is still positive, even if growth is decelerating.
The Peptide Wild Card
The most intriguing element of the story lies ahead. Peptides have been flagged as the next major growth driver, both internally by the company and externally by analysts following the space. If the FDA proceeds with an anticipated recategorization in July, Hims & Hers could find itself in a uniquely advantaged position: the only US-based domestic facility with FDA approval to compound its own peptides. That would represent a meaningful first-mover advantage and a credible path back to differentiation in a competitive landscape.
The catch is that none of this materialized in the current quarter's results. The peptide opportunity is a forward-looking thesis, not a present-day cash flow story. Investors who had been bidding the stock up in anticipation are now confronting the gap between promise and performance.
How the Street Is Reading It
Despite the rough quarter, sentiment on Wall Street has not collapsed. JPMorgan maintained its overweight rating and Canaccord kept its buy rating on the shares, suggesting that analysts still see the long-term thesis as intact even if the near term is messy. The market is essentially being asked to look past a difficult transition period in exchange for the option value embedded in the peptide opportunity.
Trading the Indifference
For options traders, a stock caught between a damaged short-term picture and a potentially powerful long-term catalyst presents a particular kind of opportunity. The chart shows significant overhead resistance around the $30 level, suggesting that meaningful upside is going to be hard to come by in the immediate term. With competition from Novo Nordisk and Eli Lilly now in full force, and the company having to structure deals rather than dictate terms, near-term appreciation looks constrained.
A short-term indifferent stance lends itself to selling an out-of-the-money call spread. A June 30/32 call spread brings in roughly 40 cents in premium, leaves nearly 15% of upside before the trade is challenged, and offers about a 25% return on risk over the next month and a half. The structure expresses the view that the stock will struggle to find its footing while still allowing room for normal price action. If the peptide story materializes later in the year, that becomes a separate, longer-dated thesis to play.
The Road Ahead
Hims & Hers is in the awkward middle of a transition that was forced upon it rather than chosen. The compounded GLP-1 advantage that defined its rise is gone, the partnerships with branded drug makers are costly, and the subscriber growth that supports the broader thesis is slowing. The peptide opportunity is real and could be transformational, but it remains a future event subject to regulatory timing and execution.
In the meantime, the stock is likely to consolidate as the market digests what is essentially a reset of expectations. The first-mover advantage may yet materialize, and patient investors with a longer time horizon may be rewarded if peptides become the engine that restores the company's growth narrative. For now, however, the gap between the story being told and the numbers being reported has become too wide to ignore, and the market has responded accordingly.